Brokerages expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will post earnings of $0.02 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.08 and the lowest is ($0.04). Amphastar Pharmaceuticals posted earnings per share of $0.14 during the same quarter last year, which would suggest a negative year over year growth rate of 85.7%. The business is expected to announce its next earnings results on Tuesday, November 14th.
According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $0.26 per share for the current fiscal year, with EPS estimates ranging from $0.11 to $0.39. For the next year, analysts forecast that the company will post earnings of $0.66 per share, with EPS estimates ranging from $0.37 to $0.92. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $63.40 million. During the same period in the previous year, the business posted $0.23 earnings per share. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year.
Several equities research analysts have recently issued reports on AMPH shares. Wells Fargo & Company reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Saturday, July 22nd. BidaskClub lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Needham & Company LLC raised their target price on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, September 27th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $19.00 target price on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $20.17.
In other news, Director Richard K. Prins sold 5,000 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $14.80, for a total transaction of $74,000.00. Following the completion of the transaction, the director now owns 33,844 shares in the company, valued at approximately $500,891.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Diane G. Gerst sold 8,444 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $18.87, for a total value of $159,338.28. The disclosure for this sale can be found here. Insiders have sold a total of 126,380 shares of company stock valued at $2,268,933 in the last quarter. 11.10% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the company. Argent Capital Management LLC bought a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $1,069,000. The Manufacturers Life Insurance Company grew its stake in shares of Amphastar Pharmaceuticals by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock worth $512,000 after acquiring an additional 312 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Amphastar Pharmaceuticals by 25.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,331,842 shares of the company’s stock worth $23,786,000 after acquiring an additional 270,654 shares during the period. Parametric Portfolio Associates LLC grew its stake in shares of Amphastar Pharmaceuticals by 72.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 45,615 shares of the company’s stock worth $815,000 after acquiring an additional 19,091 shares during the period. Finally, Nordea Investment Management AB grew its stake in shares of Amphastar Pharmaceuticals by 12.8% during the 2nd quarter. Nordea Investment Management AB now owns 115,607 shares of the company’s stock worth $2,065,000 after acquiring an additional 13,121 shares during the period. Institutional investors own 44.26% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://ledgergazette.com/2017/10/08/0-02-eps-expected-for-amphastar-pharmaceuticals-inc-amph-this-quarter.html.
Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 0.11% during trading on Tuesday, reaching $18.94. 86,049 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $16.37 and its 200-day moving average price is $16.12. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $21.75. The firm has a market cap of $874.93 million, a price-to-earnings ratio of 245.97 and a beta of 1.69.
Amphastar Pharmaceuticals declared that its board has authorized a stock repurchase program on Wednesday, August 9th that permits the company to buyback $20.00 million in shares. This buyback authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.